Literature DB >> 10379991

Interaction of the anticancer agent Taxol (paclitaxel) with phospholipid bilayers.

C Bernsdorff1, R Reszka, R Winter.   

Abstract

Taxol (paclitaxel), a promising agent for use in ovarian and breast cancer, was incorporated into lipid vesicles (liposomes) composed of different saturated and unsaturated phosphatidylcholines, as well as saturated phosphatidylcholines mixed with the anionic phospholipid 1,2-dimyristoyl-sn-glycero-3-phosphatidylserine (DMPS) at different molar ratios, to yield information about Taxol-liposome interactions. For the physicochemical characterization of the thermodynamic, structural, and dynamic properties of these mixtures, differential scanning calorimetry (DSC), steady-state fluorescence depolarization, and Fourier transform IR spectroscopy was used. Time-dependent DSC measurements on 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC)/Taxol mixtures of different concentrations were performed to yield information on the long-term stability of Taxol-liposome complexes. Partitioning of Taxol into saturated lipid bilayers results in changes of membrane physical properties, such as phase transition temperatures and lipid order parameter, that are different from those observed for unsaturated and charged phospholipid bilayers. Taxol incorporated into saturated phospholipids changes their thermotropic phase behavior: it reduces the lipid order parameter (i.e., has a "fluidizing" effect) in the gel phase of the lipid bilayers. On the contrary, partitioning of Taxol into unsaturated fluid phospholipid bilayers has a slight "rigidization" effect. The saturated lipid bilayer systems DPPC and 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine/DMPS have been identified with the highest incorporation efficiency for Taxol and are thus candidates for drug vehicles that can improve the therapeutic efficacy of Taxol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10379991     DOI: 10.1002/(sici)1097-4636(199908)46:2<141::aid-jbm2>3.0.co;2-u

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  14 in total

1.  Liposomes as multicompartmental carriers for multidrug delivery in anticancer chemotherapy.

Authors:  Donato Cosco; Donatella Paolino; Jessica Maiuolo; Diego Russo; Massimo Fresta
Journal:  Drug Deliv Transl Res       Date:  2011-02       Impact factor: 4.617

2.  Rational Design of Cholesterol Derivative for Improved Stability of Paclitaxel Cationic Liposomes.

Authors:  Jasmin Monpara; Chryso Kanthou; Gillian M Tozer; Pradeep R Vavia
Journal:  Pharm Res       Date:  2018-03-08       Impact factor: 4.200

3.  A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug.

Authors:  Phillip J Stevens; Masaru Sekido; Robert J Lee
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

4.  Fluorescence anisotropy, FT-IR spectroscopy and 31-P NMR studies on the interaction of paclitaxel with lipid bilayers.

Authors:  Anand Babu Dhanikula; Ramesh Panchagnula
Journal:  Lipids       Date:  2008-05-06       Impact factor: 1.880

5.  Distinct solubility and cytotoxicity regimes of paclitaxel-loaded cationic liposomes at low and high drug content revealed by kinetic phase behavior and cancer cell viability studies.

Authors:  Victoria M Steffes; Meena M Murali; Yoonsang Park; Bretton J Fletcher; Kai K Ewert; Cyrus R Safinya
Journal:  Biomaterials       Date:  2017-08-17       Impact factor: 12.479

6.  PEGylation of Paclitaxel-Loaded Cationic Liposomes Drives Steric Stabilization of Bicelles and Vesicles thereby Enhancing Delivery and Cytotoxicity to Human Cancer Cells.

Authors:  Victoria M Steffes; Zhening Zhang; Scott MacDonald; John Crowe; Kai K Ewert; Bridget Carragher; Clinton S Potter; Cyrus R Safinya
Journal:  ACS Appl Mater Interfaces       Date:  2019-12-24       Impact factor: 9.229

7.  A liposomal formulation able to incorporate a high content of Paclitaxel and exert promising anticancer effect.

Authors:  Pei Kan; Chih-Wan Tsao; Ae-June Wang; Wu-Chou Su; Hsiang-Fa Liang
Journal:  J Drug Deliv       Date:  2010-10-11

8.  Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.

Authors:  Jayaganesh V Natarajan; Marcus Ang; Anastasia Darwitan; Sujay Chattopadhyay; Tina T Wong; Subbu S Venkatraman
Journal:  Int J Nanomedicine       Date:  2012-01-05

9.  Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity.

Authors:  Yarong Liu; Jinxu Fang; Yu-Jeong Kim; Michael K Wong; Pin Wang
Journal:  Mol Pharm       Date:  2014-04-07       Impact factor: 4.939

10.  Biomimetic proteolipid vesicles for targeting inflamed tissues.

Authors:  R Molinaro; C Corbo; J O Martinez; F Taraballi; M Evangelopoulos; S Minardi; I K Yazdi; P Zhao; E De Rosa; M B Sherman; A De Vita; N E Toledano Furman; X Wang; A Parodi; E Tasciotti
Journal:  Nat Mater       Date:  2016-05-23       Impact factor: 43.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.